|
| 38093030 | Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden. | Pharmacoecon Open | 2024 |
| 37031604 | Compliance to adjuvant endocrine therapy and survival in breast cancer patients. | Cancer Treat Res Commun | 2023 |
| 37556775 | Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial. | J Clin Oncol | 2023 |
| 38070906 | ProFertil study protocol for the investigation of gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy aiming at fertility protection of young women and teenagers with cancer in Sweden-a phase III randomised double-blinded placebo-controlled study. | BMJ Open | 2023 |
| 37541279 | Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups. | Lancet Oncol | 2023 |
| 37607325 | De Novo Oligometastatic Breast Cancer. | J Clin Oncol | 2023 |
| 37310797 | Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG). | Oncologist | 2023 |
| 36228963 | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. | Ann Oncol | 2022 |
| 35576695 | Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force. | ESMO Open | 2022 |
| 33191817 | Delta NT-proBNP predicts cardiotoxicity in HER2-positive breast cancer patients treated with trastuzumab. | Acta Oncol | 2021 |
| 34876602 | Discordance of PIK3CA and TP53 mutations between breast cancer brain metastases and matched primary tumors. | Sci Rep | 2021 |
| 34491813 | Breaking Bad News in Cancer Care: Ethiopian Patients Want More Information Than What Family and the Public Want Them to Have. | JCO Glob Oncol | 2021 |
| 34388695 | Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up. | Breast | 2021 |
| 34273877 | Real world data on adjuvant treatment of older HER2-positive breast cancer patients - A single institution experience through 8 years. | Cancer Treat Res Commun | 2021 |
| 34183353 | Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. | Cancer Discov | 2021 |
| 34312396 | Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. | NPJ Breast Cancer | 2021 |
| 34081848 | Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer. | N Engl J Med | 2021 |
| 32427112 | Person and Family Centeredness in Ethiopian Cancer Care: Proposal for a Project for Improving Communication, Ethics, Decision Making, and Health. | JMIR Res Protoc | 2020 |
| 36094184 | Adjuvant chemotherapy and survival in women aged 70 years and older with triple-negative breast cancer: a Swedish population-based propensity score-matched analysis. | Lancet Healthy Longev | 2020 |
| 33248390 | Efficacy and tolerability of metronomic chemotherapy in patients with metastatic breast cancer - an international experience in West Sweden and in the South of Ireland. | Cancer Treat Res Commun | 2020 |
| 32504183 | Personalised medicine and the decision to withhold chemotherapy in early breast cancer with intermediate risk of recurrence - a systematic review and meta-analysis. | Eur J Clin Pharmacol | 2020 |
| 32524352 | A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns. | Breast Cancer Res Treat | 2020 |
| 32145571 | Clinical outcome of patients with brain metastases from breast cancer - A population based study over 21 years. | Breast | 2020 |
| 32168353 | Communicative challenges among physicians, patients, and family caregivers in cancer care: An exploratory qualitative study in Ethiopia. | PLoS One | 2020 |
| 29092024 | Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. | Ann Oncol | 2018 |
| 29370583 | Immune gene expression and response to chemotherapy in advanced breast cancer. | Br J Cancer | 2018 |
| 29190004 | Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer. | Breast Cancer Res Treat | 2018 |
| 28972041 | PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients. | Clin Cancer Res | 2017 |
| 28084333 | Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. | Mod Pathol | 2017 |
| 28292559 | Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. | Eur J Cancer | 2017 |
| 28441617 | The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value? | Breast | 2017 |
| 27325862 | Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. | J Clin Oncol | 2016 |
| 26276891 | Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer. | Clin Cancer Res | 2016 |
| 25361981 | Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. | Ann Oncol | 2015 |
| 25878567 | Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer. | Clin Proteomics | 2015 |
| 24399849 | Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer. | J Natl Cancer Inst | 2014 |
| 24842109 | Molecular profiling of male breast cancer - lost in translation? | Int J Biochem Cell Biol | 2014 |
| 23322522 | Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy. | Med Oncol | 2013 |
| 23868472 | Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. | Nat Commun | 2013 |
| 23968864 | Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel. | Breast | 2013 |
| 23968863 | Identification of intermediate risk breast cancer patients with 1-3 positive lymph nodes and excellent survival after tamoxifen as only systemic adjuvant therapy by use of markers of proliferation and apoptosis. | Breast | 2013 |
| 23736998 | Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial. | Breast Cancer Res Treat | 2013 |
| 21983489 | Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. | Breast | 2012 |
| 22094937 | Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial. | Breast Cancer Res Treat | 2012 |
| 20822898 | Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer. | Eur J Cancer | 2011 |
| 21110084 | Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer. | Breast Cancer Res Treat | 2011 |
| 21174610 | A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. | Acta Oncol | 2011 |
| 20413297 | Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF. | Eur J Cancer | 2010 |
| 19130322 | Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor. | Med Oncol | 2009 |
| 19549711 | Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. | Ann Oncol | 2009 |